15 October 2025
Partnering
We leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease, and Neuroscience. External innovation i...
-
23 July 2025
-
23 July 2025
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:...
-
13 May 2026
-
13 May 2026
Ipsen S.A. – Evolution of the composition of the Board of Directors
Ipsen S.A. – Evolution of the composition of the Board of Directors...
-
23 April 2026
-
23 April 2026
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
PARIS, FRANCE, 23 April 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026....
-
02 February 2026
- 1 min read
-
02 February 2026
- 1 min read
Ipsen Earns a Top Climate Rating: What is CDP, and Why Does It Matter?
Together for the Climate: Ipsen Strengthens Its Climate Commitment with CDP A-List Recognition and SBTi Approval ...
-
21 January 2026
-
21 January 2026
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbit...
-
12 March 2026
-
12 March 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership T...
-
12 February 2026
- 1 min read
-
12 February 2026
- 1 min read
FY 2025: Strong results and momentum for 2026
FY 2025 was a year of strong execution and robust performance across all therapeutic areas, driving significant topline growth and reinforcing the company’s strategic momentum. Total sales grew 10.9% at constant exchange rates (CER), supported by a solid...
-
15 April 2026
- 2 mins read
-
15 April 2026
- 2 mins read
Guillermo’s Story: Lessons from Patients’ Lives
In the pharmaceutical industry, it’s easy to focus on data, strategy, and performance metrics. But behind every decision are real people. For Guillermo Castillo Acero, Head of European Mid-Sized Markets at Ipsen, that reality became clear during a pre...
-
12 March 2025
-
12 March 2025
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen’s Execu...